EGFR and intrahepatic cholangiocarcinoma: These new models were used in a small 111 compound drug screen in the background of three different FGFR inhibitors, infigratinib, futibatinib, and rogaratinib, yielding a combination strategy with EGFR inhibition that improved efficacy as well as the ability to rescue resistance to FGFR inhibitors in ICC models20.